Oral chemotherapy in the treatment of hormone-refractory prostate cancer

Drugs

Volumn 58, Issue SUPPL. 3, 1999, Pages 127-131

  Pienta, Kenneth J ^a,b   Kamradt, Jeffrey M ^a   Smith, David C ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; ESTRAMUSTINE; ETOPOSIDE; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; NAUSEA; PROSTATE CANCER; VEIN THROMBOSIS;

EID: 0033497147     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958003-00017     Document Type: Conference Paper

References (31)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 5-27
2. Berges RR, Vukanovic J, Epstein JI, et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Can Res 1995; 1: 473-80
3. Isaacs JT. Hormonally responsive vs unresponsive progression of prostatic canter to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat prostatic adenocarcinomas. Cancer Res 1982; 42: 5010-4
4. Eisenberger MA. Chemotherapy for prostate carcinoma. NCl Monogr 1988; 7: 151-63
5. Murphy GP, Slack NH, Mittelman A. Use of estramustine phosphate in prostate cancer by the National Prostatic Cancer Project and by Roswell Park Memorial Institute. Urology 1984; 23: 54-63
6. Hartley-Asp B, Kruse E. Nuclear protein matrix as a target for estramustine-induced cell death. Prostate 1986; 9: 387-95
7. Nelson WG, Pienta KJ, Barrack ER, et al. The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Biophys Chem 1986; 15: 457-75
8. Ciejek EM, Tsai M, O'Malley BW. Actively transcribed genes are associated with the nuclear matrix. Nature 1983; 306: 607-9
9. Hussain MH, Pienta KJ, Redman BG, et al. Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer 1994; 74: 100-3
10. Walther PJ, Williams SD, Troner M, et al. Phase II study of etoposide for carcinoma of the prostate. Cancer Treat Rep 1986; 70: 771-2
11. Scher HI, Sternberg C, Heston WD, et al. Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. Cancer Chemother Pharmacol 1986; 18: 24-6
12. Nelson WG, Liu LF, Coffey DS. Newly replicated DNA is associated with DNA topoisomcrase II in cultured rat prostatic adenocarcinoma cells. Nature 1986; 322: 187-9
13. Kaufmann SH, Shaper JH. Association of topoisomerase II with the hepatoma cell nuclear matrix: the role of intermolecular disulfide bond formation. Exp Cell Res 1991; 192: 811-23
14. Pienta KJ, Lehr JE. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol 1993; 149: 1622-5
15. Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12: 2005-12
16. Pienta KJ, Redman BG, Bandekar R, et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 1997; 50: 401-6
17. Dimopoulos MA, Panopoulos C, Bamia C, et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 1997; 50; 754-8
18. Stearns ME, Tew KD. Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res 1985; 45: 3891-7
19. Dexeus F, Logothetis CJ, Samuels ML, et al. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 1985; 69: 885-6
20. Batra S, Karlsson R, Witt L. Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells. Int J Cancer 1996; 68: 644-9
21. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone refractory prostate cancer. J Clin Oncol 1992; 10: 1754-61
22. Seidman AD, Scher HI, Petrylak D, et al. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial endpoint for hormone refractory prostatic cancer. J Urol 1992; 147:931-4
23. Attivissimo LA, Fetten JV, Kreis W. Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Am J Clin Oncol 1996; 19: 581-3
24. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). New Engl J Med 1995; 332: 1004-14
25. Roytta M, Laine KM, Harkonen P. Morphological studies on the effect of taxol on cultured human prostate cancer cells. Prostate 1987; 11: 95-106
26. Roth BJ, Yeap BY, Wilding G, et al. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993; 72: 2457-60
27. Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 1992; 52: 4433-40
28. Pienta KJ, Naik H, Lehr JE. Effect of estramustine, etoposide and taxol on prostate cancer cell growth in vitro and in vivo. Urology 1996; 48: 164-70
29. Hudes GR, Nathan FE, Khater C, et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol 1995; 22 Suppl. 12: 41-5
30. Pienta KJ, Esper PS, Smith DC. The oral regimen of Cytoxan®, prednisone and diethylstilbestrol is an active, non-toxic treatment for patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 1997; 16: 310A
31. Maulard-Durdux C, Dufour B, Hennequin C, et al: Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 1996; 77: 1144-8